U.S. Pharmacopeia Offers Help In Aftermath Of China's New Scandal, Cover-up Involving Deliberate Adulteration
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Repercussions following China's new contamination scandal involving the toxic chemical melamine are rippling across the Pacific, with potential importers in the U.S. alarmed over the effectiveness of China's food and drug safety system
You may also be interested in...
Cost Of China Healthcare Reforms Exceeds RMB 1 Trillion; Government Raises Reimbursement Ceilings
BEIJING - As leaders in China's central government gathered last week in Beijing to take part in the National People's Congress, they revealed that the price of ever-expanding healthcare reforms, ultimately aimed at providing universal coverage and commonly affordable medical care through measures including the national Essential Drug List, has already risen above RMB 1 trillion
Cost Of China Healthcare Reforms Exceeds RMB 1 Trillion; Government Raises Reimbursement Ceilings
BEIJING - As leaders in China's central government gathered last week in Beijing to take part in the National People's Congress, they revealed that the price of ever-expanding healthcare reforms, ultimately aimed at providing universal coverage and commonly affordable medical care through measures including the national Essential Drug List, has already risen above RMB 1 trillion
China Takes "Baby Steps" Toward More Open Supplement Regulation
China's health product regulators are taking "baby steps" toward more streamlined approval of supplements, but multi-ingredient products likely will face a series of hurdles before market, says Jeff Crowther, former executive director of the Natural Products Association's Beijing office